Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

An interview with Scott Summerfield: Emerging technologies in the bioanalytical field

6 Dec 2017
General interest

For our Spotlight on emerging technologies, we spoke to Scott Summerfield, Worldwide Head of Bioanalysis at GSK (Brentford, UK) about some of the technologies emerging in the bioanalytical field, the advantages and challenges faced with these techniques, and the scope for these technologies to advance further.

Back to our Spotlight – Emerging technologies: DMPK and bioanalysis of small molecules

 

Top content

  • AI-powered liquid biopsy could uncover early signs of liver disease
  • US FDA takes further steps to streamline biosimilar development
  • What to look out for at Analytica 2026

Related tags

emerging technologies interview video
Previous article Next article

Related articles

16 SEP 2019 REGULATED BIOANALYSIS
GCC ICH M10: thoughts from Chad Briscoe
30 MAR 2020 AN AUTHOR'S PERSPECTIVE
A solvent-free future? Solid-phase microextraction with Janusz Pawliszyn
29 NOV 2017 BIOPHARMACEUTICALS
Paper-based dried sampling approaches for PK analysis: limitations and possibilities
27 MAR 2018 DATA PROCESSING AND INTERPRETATION
Scott Summerfield: 5 top tips for mass spectrometry
29 MAY 2018 LARGE MOLECULES
Top 5 techniques and tips for choosing old vs new technologies
13 NOV 2017 GENERAL INTEREST
Emerging technologies: DMPK and bioanalysis of small molecules infographic
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone